Tandem Diabetes Care First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 05/02 11:26

Tandem Diabetes Care (NASDAQ:TNDM) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$234.4m (up 22% from 1Q 2024).
  • Net loss: US$130.6m (loss widened by 206% from 1Q 2024).
  • US$1.97 loss per share (further deteriorated from US$0.65 loss in 1Q 2024).
earnings-and-revenue-growth
NasdaqGM:TNDM Earnings and Revenue Growth May 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tandem Diabetes Care Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 13% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Tandem Diabetes Care that you need to take into consideration.